Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Chronic Heart Failure

  Free Subscription

Articles published in Am Heart J

Retrieve available abstracts of 197 articles:
HTML format

Single Articles

    July 2021
  1. MOGHADDAM N, Malhi N, Toma M
    Impact of Oral Soluble Guanylate Cyclase Stimulators in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Am Heart J. 2021 Jul 17. pii: S0002-8703(21)00182.
    PubMed     Abstract available

  2. NUNEZ-GIL IJ, Olier I, Feltes G, Viana-Llamas MC, et al
    Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
    Am Heart J. 2021;237:104-115.
    PubMed     Abstract available

    June 2021
  3. JENSEN J, Omar M, Moller JE, Schou M, et al
    Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial".
    Am Heart J. 2021;236:106.

  4. PATOULIAS D, Papadopoulos C, Doumas M
    Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
    Am Heart J. 2021;236:104-105.

    May 2021
  5. FUDIM M, Spates T, Sun JL, Kittipibul V, et al
    Early Diuretic Strategies and the Association With In-Hospital and Post-Discharge Outcomes in Acute Heart Failure.
    Am Heart J. 2021 May 27. pii: S0002-8703(21)00140.
    PubMed     Abstract available

  6. RODRIGUES DOS SANTOS M, Alves MNN, Jordao CP, Pinto CEN, et al
    Sacubitril/Valsartan Versus Enalapril on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction: A Randomized, Double-Blind, Active-Controlled Study: Sacubitril/Valsartan and Enalapril on Peak VO2 in Patients with Heart Failur
    Am Heart J. 2021 May 13. pii: S0002-8703(21)00125.
    PubMed     Abstract available

  7. CHEN Y, Lawrence J, Stockbridge N
    Days Alive Out of Hospital in Heart Failure: Insights from the PARADIGM-HF and CHARM Trials.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00119.
    PubMed     Abstract available

  8. GRUBB CS, Truby LK, Topkara VK, Bohnen MS, et al
    Advanced Heart Failure Patients Supported with Ambulatory Inotropic Therapy: What Defines Success of Therapy?
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00121.
    PubMed     Abstract available

  9. LEE DS, Straus SE, Austin PC, Mohamed S, et al
    Rationale and Design of the Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial: A Stepped Wedge Cluster Randomized Trial.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00123.
    PubMed     Abstract available

  10. SINGH JP, Walsh MN, Kubo SH, Auricchio A, et al
    Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial.
    Am Heart J. 2021;235:158-162.
    PubMed     Abstract available

    April 2021
    Letter to the Editor by Mehmood regarding the article "Outcomes and Cost Among Medicare Beneficiaries Hospitalized for Heart Failure Assigned to Accountable Care Organizations".
    Am Heart J. 2021;234:132.

    March 2021
  12. BROOKSBANK JA, Greene SJ, Harris HM, Stebbins A, et al
    Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
    Am Heart J. 2021;233:1-4.
    PubMed     Abstract available

    February 2021
  13. SHAHZEB KHAN M, Kristensen SL, Vaduganathan M, Kober L, et al
    Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00054.
    PubMed     Abstract available

  14. JENTZER JC, Ahmed AM, Vallabhajosyula S, Burstein B, et al
    Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time.
    Am Heart J. 2021;232:94-104.
    PubMed     Abstract available

    January 2021
  15. ALBERT NM, Tyson RJ, Hill CL, DeVore AD, et al
    Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbiditie
    Am Heart J. 2021 Jan 23. pii: S0002-8703(21)00028.
    PubMed     Abstract available

  16. R P, G W, J R, M T, et al
    A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00016.
    PubMed     Abstract available

  17. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    PubMed     Abstract available

  18. ISRAR MZ, Bernieh D, Salzano A, Cassambai S, et al
    Association of gut-related metabolites with outcome in acute heart failure.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00010.
    PubMed     Abstract available

  19. ADACHI Y, Yamamoto M, Shimura T, Yamaguchi R, et al
    Late kidney injury after transcatheter aortic valve replacement.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00011.
    PubMed     Abstract available

  20. YERASI C, Tripathi B, Wang Y, Forrestal BJ, et al
    National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016.
    Am Heart J. 2021;231:25-31.
    PubMed     Abstract available

    December 2020
  21. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    PubMed     Abstract available

  22. SARRAJU A, Li J, Cannon CP, Chang TI, et al
    Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
    Am Heart J. 2020 Dec 20. pii: S0002-8703(20)30407.
    PubMed     Abstract available

  23. VAISHNAV J, Hubbard A, Chasler JE, Lepley D, et al
    Management of Heart Failure in Cardiac Amyloidosis Using an Ambulatory Diuresis Clinic.
    Am Heart J. 2020 Dec 19. pii: S0002-8703(20)30411.
    PubMed     Abstract available

  24. NUCCIA M, Claudia M, Alice S, Guido T, et al
    Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: rationale and design of the randomized Altshock- 2 trial.
    Am Heart J. 2020 Dec 15. pii: S0002-8703(20)30399.
    PubMed     Abstract available

    November 2020
  25. HAMO CE, Fonarow GC, Greene SJ, Vaduganathan M, et al
    Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure.
    Am Heart J. 2020 Nov 29. pii: S0002-8703(20)30397.
    PubMed     Abstract available

  26. RASLAN IR, Ross HJ, Fowler RA, Scales DC, et al
    The Associations Between Direct and Delayed Critical Care Unit Admission with Mortality and Readmissions Among Patients with Heart Failure.
    Am Heart J. 2020 Nov 6. pii: S0002-8703(20)30369.
    PubMed     Abstract available

    October 2020
  27. COX ZL, Collins SP, Aaron M, Hernandez GA, et al
    Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30357.
    PubMed     Abstract available

  28. BOAS R, Thune JJ, Pehrson S, Kober L, et al
    Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30359.
    PubMed     Abstract available

  29. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available

  30. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    PubMed     Abstract available

  31. FRIEDMAN DJ, Emerek K, Kisslo J, Sogaard P, et al
    Left bundle branch block is associated with a similar Dyssynchronous phenotype in heart failure patients with Normal and reduced ejection fractions.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30338.
    PubMed     Abstract available

  32. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    PubMed     Abstract available

  33. PARADIES V, Zheng H, Bulluck H, Hausenloy DJ, et al
    Response to the letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:117-118.

  34. ROSSBERG N, Kirresh A, Ahmad M
    Letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:116.

    September 2020
  35. BLUMER V, Greene SJ, Ortiz M, Kittipibul V, et al
    In-hospital outcomes after bariatric surgery in patients with heart failure.
    Am Heart J. 2020 Sep 26. pii: S0002-8703(20)30260.
    PubMed     Abstract available

  36. MENTZ RJ, Xu H, O'Brien EC, Thomas L, et al
    PROVIDE-HF primary results: Patient-reported outcomes inVestigation following initiation of drug therapy with Entresto (Sacubitril/valsartan) in heart failure.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30265.
    PubMed     Abstract available

  37. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    PubMed     Abstract available

  38. TAKADA S, Kondo T, Yasunaga M, Watanabe S, et al
    Early rehabilitation in older patients hospitalized with acute decompensated heart failure: A retrospective cohort study.
    Am Heart J. 2020 Sep 18. pii: S0002-8703(20)30262.
    PubMed     Abstract available

  39. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    PubMed     Abstract available

    August 2020
  40. VENECHUK G, Khazanie P, Page RL, Knoepke CE, et al
    An electronically delivered, patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial.
    Am Heart J. 2020 Aug 28. pii: S0002-8703(20)30243.
    PubMed     Abstract available

  41. HONIGBERG MC, Pirruccello JP, Aragam K, Sarma AA, et al
    Menopausal Age and Left Ventricular Remodeling by Cardiac Magnetic Resonance Imaging Among 14,550 Women.
    Am Heart J. 2020 Aug 19. pii: S0002-8703(20)30235.
    PubMed     Abstract available

  42. BERRY N, Mauri L, Feldman T, Komtebedde J, et al
    Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).
    Am Heart J. 2020;226:222-231.
    PubMed     Abstract available

    July 2020
  43. JENSEN J, Omar M, Kistorp C, Poulsen MK, et al
    Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
    Am Heart J. 2020;228:47-56.
    PubMed     Abstract available

  44. BHARDWAJ B, Cohen DJ, Vemulapalli S, Kosinski AS, et al
    Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry.
    Am Heart J. 2020;228:57-64.
    PubMed     Abstract available

  45. OLSEN CR, Mentz RJ, Anstrom KJ, Page D, et al
    Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure.
    Am Heart J. 2020;229:1-17.
    PubMed     Abstract available

    June 2020
  46. ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Martinez-Amezcua P, Cabello-Lopez A, et al
    A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study).
    Am Heart J. 2020;227:31-39.
    PubMed     Abstract available

  47. VAN OORT S, Beulens JWJ, van Ballegooijen AJ, Handoko ML, et al
    Modifiable lifestyle factors and heart failure: A Mendelian randomization study.
    Am Heart J. 2020;227:64-73.
    PubMed     Abstract available

  48. JOSEPH P, Dokainish H, McCready T, Budaj A, et al
    A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.
    Am Heart J. 2020;227:56-63.
    PubMed     Abstract available

    May 2020
  49. KUNO T, Takahashi M, Obata R, Maeda T, et al
    Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City.
    Am Heart J. 2020 May 15. pii: S0002-8703(20)30141.
    PubMed     Abstract available

  50. LUO N, Hammill BG, DeVore AD, Xu H, et al
    Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations.
    Am Heart J. 2020;226:13-23.
    PubMed     Abstract available

  51. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    PubMed     Abstract available

  52. KAHN PA, Riello RJ 3rd, Ahmad T, Desai NR, et al
    Adoption of sacubitril-valsartan in the Medicare population.
    Am Heart J. 2020;223:81-83.

  53. FUDIM M, Dalgaard F, Al-Khatib SM, J Friedman D, et al
    Future research prioritization in cardiac resynchronization therapy.
    Am Heart J. 2020;223:48-58.
    PubMed     Abstract available

    April 2020
  54. BILCHICK KC, Wang Y, Curtis JP, Cheng A, et al
    Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
    Am Heart J. 2020;222:93-104.
    PubMed     Abstract available

    March 2020
  55. WU CM, Albert NM, Gluckman TJ, Lu D, et al
    Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program.
    Am Heart J. 2020;224:77-84.
    PubMed     Abstract available

  56. PARADIES V, Zheng H, Chan MHH, Chan MYY, et al
    Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.
    Am Heart J. 2020;224:1-9.
    PubMed     Abstract available

  57. NAPOLI C, Benincasa G, Donatelli F, Ambrosio G, et al
    Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics.
    Am Heart J. 2020;224:113-128.
    PubMed     Abstract available

    February 2020
  58. MENTZ RJ, DeVore AD, Tasissa G, Heitner JF, et al
    PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
    Am Heart J. 2020;223:98-105.
    PubMed     Abstract available

  59. COOPER LB, Psotka MA, Sinha S, Nallamothu BK, et al
    Specificity of administrative coding for older adults with acute heart failure hospitalizations.
    Am Heart J. 2020;223:1-2.

    January 2020
  60. DUENGEN HD, Kim RJ, Zahger D, Orvin K, et al
    Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
    Am Heart J. 2020;224:129-137.
    PubMed     Abstract available

  61. UDELSON JE, Lewis GD, Shah SJ, Zile MR, et al
    Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved
    Am Heart J. 2020;222:183-190.
    PubMed     Abstract available

  62. ARASHI H, Sato T, Kobashigawa J, Luikart H, et al
    Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.
    Am Heart J. 2020;222:30-37.
    PubMed     Abstract available

  63. LEERINK JM, Feijen ELAM, van der Pal HJH, Kok WEM, et al
    Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study.
    Am Heart J. 2020;219:89-98.
    PubMed     Abstract available

  64. LU DY, Ventoulis I, Liu H, Kudchadkar SM, et al
    Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy.
    Am Heart J. 2020;219:58-69.
    PubMed     Abstract available

  65. YAO X, McCoy RG, Friedman PA, Shah ND, et al
    ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial.
    Am Heart J. 2020;219:31-36.
    PubMed     Abstract available

    December 2019
  66. ELMING MB, Hammer-Hansen S, Voges I, Nyktari E, et al
    Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI.
    Am Heart J. 2019 Dec 24. pii: S0002-8703(19)30351.
    PubMed     Abstract available

  67. KALRA R, Shenoy C
    Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?
    Am Heart J. 2019 Dec 17. pii: S0002-8703(19)30352.

  68. LOEB M, Dokainish H, Dans A, Palileo-Villanueva LM, et al
    Corrigendum to "Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design" [212 (2019) 36-44].
    Am Heart J. 2019 Dec 12. pii: S0002-8703(19)30323.

  69. TRIPOLT NJ, Kolesnik E, Pferschy PN, Verheyen N, et al
    Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Am Heart J. 2019;221:39-47.
    PubMed     Abstract available

    November 2019
  70. FUDIM M, Kelly JP, Jones AD, AbouEzzeddine OF, et al
    Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
    Am Heart J. 2019;220:97-107.
    PubMed     Abstract available

  71. LORING Z, Shrader P, Allen LA, Blanco R, et al
    Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
    Am Heart J. 2019;219:21-30.
    PubMed     Abstract available

    October 2019
  72. SLEE A, Saksena S
    Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial.
    Am Heart J. 2019;220:1-11.
    PubMed     Abstract available

  73. JENTZER JC, Baran DA, van Diepen S, Barsness GW, et al
    Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients.
    Am Heart J. 2019;219:37-46.
    PubMed     Abstract available

  74. DEVORE AD, Granger BB, Fonarow GC, Al-Khalidi HR, et al
    Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF.
    Am Heart J. 2019;220:41-50.
    PubMed     Abstract available

  75. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    PubMed     Abstract available

  76. CZOBOR P, Hung YY, Baer D, McGlothlin D, et al
    Amyloid cardiomyopathy in a large integrated health care system.
    Am Heart J. 2019;216:42-52.
    PubMed     Abstract available

    September 2019
  77. HORNE BD, Roberts CA, Rasmusson KD, Buckway J, et al
    Risk score-guided multidisciplinary team-based Care for Heart Failure Inpatients is associated with lower 30-day readmission and lower 30-day mortality.
    Am Heart J. 2019;219:78-88.
    PubMed     Abstract available

  78. UNNI RR, Lee SF, Thabane L, Connolly S, et al
    Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trial.
    Am Heart J. 2019;220:116-126.
    PubMed     Abstract available

  79. VAN MOURIK Y, Rutten FH, Bertens LCM, Cramer MJM, et al
    Clinical research study implementation of case-finding strategies for heart failure and chronic obstructive pulmonary disease in the elderly with reduced exercise tolerance or dyspnea: A cluster randomized trial.
    Am Heart J. 2019;220:73-81.
    PubMed     Abstract available

  80. FERREIRA JP, Rossignol P, Dewan P, Lamiral Z, et al
    Income level and inequality as complement to geographical differences in cardiovascular trials.
    Am Heart J. 2019;218:66-74.
    PubMed     Abstract available

    August 2019
  81. BHATT AS, Luo N, Solomon N, Pagidipati NJ, et al
    International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Am Heart J. 2019;218:57-65.
    PubMed     Abstract available

  82. PIOTROWICZ E, Piotrowicz R, Opolski G, Pencina M, et al
    Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial-Study design and description of the intervention.
    Am Heart J. 2019;217:148-158.
    PubMed     Abstract available

    July 2019
  83. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    PubMed     Abstract available

  84. ADAMO M, Grasso C, Capodanno D, Rubbio AP, et al
    Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry.
    Am Heart J. 2019;217:32-41.
    PubMed     Abstract available

    June 2019
  85. HALL TS, von Lueder TG, Zannad F, Rossignol P, et al
    Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.
    Am Heart J. 2019;215:83-90.
    PubMed     Abstract available

  86. GALLI E, Hubert A, Le Rolle V, Hernandez A, et al
    Myocardial constructive work and cardiac mortality in resynchronization therapy candidates.
    Am Heart J. 2019;212:53-63.
    PubMed     Abstract available

    May 2019
  87. CLAEYS MJ, Coussement P, Dubois P, Garcia-Dorado D, et al
    Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial.
    Am Heart J. 2019 May 30. pii: S0002-8703(19)30129.

  88. LINDENFELD J, Abraham WT, Maisel A, Zile M, et al
    Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF).
    Am Heart J. 2019;214:18-27.

    April 2019
  89. WARRAICH HJ, Allen LA, Blue LJ, Chaussee EL, et al
    Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation: An analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for
    Am Heart J. 2019;213:91-96.
    PubMed     Abstract available

  90. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    PubMed     Abstract available

  91. YANDRAPALLI S, Sanaani A, Harikrishnan P, Aronow WS, et al
    Cardiogenic shock during heart failure hospitalizations: Age-, sex-, and race-stratified trends in incidence and outcomes.
    Am Heart J. 2019;213:18-29.
    PubMed     Abstract available

  92. WANG A, Chu VH, Athan E, Delahaye F, et al
    Association between the timing of surgery for complicated, left-sided infective endocarditis and survival.
    Am Heart J. 2019;210:108-116.
    PubMed     Abstract available

    March 2019
  93. EDMONSTON DL, Wu J, Matsouaka RA, Yancy C, et al
    Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients.
    Am Heart J. 2019;212:101-112.
    PubMed     Abstract available

  94. LOEB M, Dokainish H, Dans A, Palileo-Villanueva LM, et al
    Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.
    Am Heart J. 2019;212:36-44.
    PubMed     Abstract available

  95. LECLERCQ C, Burri H, Curnis A, Delnoy PP, et al
    Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP-PHASE II).
    Am Heart J. 2019;209:1-8.
    PubMed     Abstract available

    January 2019
  96. SHARMA A, Mentz RJ, Granger BB, Heitner JF, et al
    Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial.
    Am Heart J. 2019;211:22-33.
    PubMed     Abstract available

  97. ZIAEIAN B, Hernandez AF, DeVore AD, Wu J, et al
    Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry.
    Am Heart J. 2019;211:1-10.
    PubMed     Abstract available

  98. ALVI RM, Afshar M, Neilan AM, Tariq N, et al
    Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.
    Am Heart J. 2019;210:39-48.
    PubMed     Abstract available

    December 2018
  99. SANDHU AT, Heidenreich PA
    Comparison of the change in heart failure readmission and mortality rates between hospitals subject to hospital readmission reduction program penalties and critical access hospitals.
    Am Heart J. 2018;209:63-67.
    PubMed     Abstract available

  100. BURSTEIN DS, Shamszad P, Dai D, Almond CS, et al
    Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults.
    Am Heart J. 2018;209:9-19.
    PubMed     Abstract available

    November 2018
  101. CANEPA M, Ameri P, Lucci D, Nicolosi GL, et al
    Modes of death and prognostic outliers in chronic heart failure.
    Am Heart J. 2018;208:100-109.
    PubMed     Abstract available

  102. GEENEN LW, Baggen VJM, Koudstaal T, Boomars KA, et al
    The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach.
    Am Heart J. 2018;208:91-99.
    PubMed     Abstract available

  103. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Abstract available

    September 2018
  104. BENCHETRIT L, Zimmerman C, Bao H, Dharmarajan K, et al
    Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates.
    Am Heart J. 2018;207:19-26.
    PubMed     Abstract available

  105. Home monitoring with IT-supported specialist management versus home monitoring alone in patients with heart failure: Design and baseline results of the SUPPORT-HF 2 randomized trial.
    Am Heart J. 2018;208:55-64.
    PubMed     Abstract available

    August 2018
  106. COLIN-RAMIREZ E, Ezekowitz JA
    Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF).
    Am Heart J. 2018;205:87-96.
    PubMed     Abstract available

  107. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    PubMed     Abstract available

    July 2018
  108. MILLER PE, Ahmad T
    Loop diuretics in heart failure: Few facts and lots of prejudice.
    Am Heart J. 2018 Jul 30. pii: S0002-8703(18)30234.

  109. FUDIM M, Loungani R, Doerfler SM, Coles A, et al
    Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial.
    Am Heart J. 2018;204:163-173.
    PubMed     Abstract available

  110. FUDIM M, O'Connor CM, Mulder H, Coles A, et al
    Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.
    Am Heart J. 2018 Jul 29. pii: S0002-8703(18)30233.
    PubMed     Abstract available

  111. MORICI N, Oliva F, Ajello S, Stucchi M, et al
    Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30217.
    PubMed     Abstract available

  112. MENTZ RJ, O'Connor CM, Granger BB, Yang H, et al
    Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30219.

  113. KETEYIAN SJ, Kerrigan DJ, Lewis B, Ehrman JK, et al
    Exercise training workloads in cardiac rehabilitation are associated with clinical outcomes in patients with heart failure.
    Am Heart J. 2018;204:76-82.
    PubMed     Abstract available

  114. KOROL S, White M, O'Meara E, Tournoux F, et al
    A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30203.
    PubMed     Abstract available

  115. DAUBERT MA, Whellan DJ, Woehrle H, Tasissa G, et al
    Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial.
    Am Heart J. 2018;201:40-48.
    PubMed     Abstract available

  116. UPADHYA B, Brubaker PH, Morgan TM, Eggebeen JD, et al
    The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial.
    Am Heart J. 2018;201:164-167.
    PubMed     Abstract available

    June 2018
  117. ARNOLD SV, Echouffo-Tcheugui JB, Lam CS, Inzucchi SE, et al
    Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
    Am Heart J. 2018;203:25-29.
    PubMed     Abstract available

  118. BALLING L, Thomsen JH, Wolsk E, Hassager C, et al
    Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise.
    Am Heart J. 2018 Jun 14. pii: S0002-8703(18)30172.

  119. AHMAD FS, French B, Bowles KH, Sevilla-Cazes J, et al
    Incorporating patient-centered factors into heart failure readmission risk prediction: A mixed-methods study.
    Am Heart J. 2018;200:75-82.
    PubMed     Abstract available

  120. LUO N, Ballew NG, O'Brien EC, Greiner MA, et al
    Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
    Am Heart J. 2018;200:134-140.
    PubMed     Abstract available

  121. JALNAPURKAR S, Zhao X, Heidenreich PA, Bhatt DL, et al
    A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.
    Am Heart J. 2018;200:127-133.
    PubMed     Abstract available

  122. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Abstract available

  123. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    PubMed     Abstract available

    May 2018
  124. MCALISTER FA, Youngson E, van Diepen S, Ezekowitz JA, et al
    Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study.
    Am Heart J. 2018 May 27. pii: S0002-8703(18)30164.
    PubMed     Abstract available

  125. SHAKIR M, Wasfy JH
    Heart failure and readmissions: Research in the public eye.
    Am Heart J. 2018;203:1-3.

  126. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    PubMed     Abstract available

  127. WAGNER J, Agostoni P, Arena R, Belardinelli R, et al
    The Role of Gas Exchange Variables in Cardiopulmonary Exercise Testing for Risk Stratification and Management of Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2018;202:116-126.
    PubMed     Abstract available

  128. CAINZOS-ACHIRICA M, Rebordosa C, Vela E, Cleries M, et al
    Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases.
    Am Heart J. 2018;202:76-83.
    PubMed     Abstract available

  129. LUK A, Groarke JD, Desai AS, Mahmood SS, et al
    First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization.
    Am Heart J. 2018 May 19. pii: S0002-8703(18)30152.
    PubMed     Abstract available

  130. AMBROSY AP, Bhatt AS, Stebbins AL, Wruck LM, et al
    Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) ran
    Am Heart J. 2018;199:97-104.
    PubMed     Abstract available

  131. VAN SPALL HGC, Lee SF, Xie F, Ko DT, et al
    Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial.
    Am Heart J. 2018;199:75-82.
    PubMed     Abstract available

  132. PICCINI JP, Connolly SJ, Abraham WT, Healey JS, et al
    A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    Am Heart J. 2018;199:51-58.
    PubMed     Abstract available

  133. AMBROSY AP, Velazquez EJ
    Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.
    Am Heart J. 2018;199:176-177.

  134. JANUZZI JL, Butler J, Fombu E, Maisel A, et al
    Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
    Am Heart J. 2018;199:130-136.
    PubMed     Abstract available

  135. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    PubMed     Abstract available

  136. AJAM T, Ajam S, Devaraj S, Mohammed K, et al
    Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
    Am Heart J. 2018;199:1-6.
    PubMed     Abstract available

  137. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    PubMed     Abstract available

    April 2018
  138. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    PubMed     Abstract available

  139. GODOWN J, Smith AH, Thurm C, Hall M, et al
    Mechanical circulatory support costs in children bridged to heart transplantation - analysis of a linked database.
    Am Heart J. 2018;201:77-85.
    PubMed     Abstract available

  140. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    PubMed     Abstract available

  141. VELAZQUEZ EJ, Morrow DA, DeVore AD, Ambrosy AP, et al
    Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Am Heart J. 2018;198:145-151.
    PubMed     Abstract available

  142. KHAZANIE P, Hellkamp AS, Fonarow GC, Curtis LH, et al
    Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry.
    Am Heart J. 2018;198:123-128.
    PubMed     Abstract available

  143. EGBE A, Khan AR, Al-Otaibi M, Said SM, et al
    Outcomes of hospitalization in adults with Fontan palliation: The Mayo Clinic experience.
    Am Heart J. 2018;198:115-122.
    PubMed     Abstract available

    March 2018
  144. SULLIVAN LT 2ND, Randolph T, Merrill P, Jackson LR 2nd, et al
    Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction.
    Am Heart J. 2018;197:43-52.
    PubMed     Abstract available

    February 2018
  145. VAN BOVEN N, Battes LC, Akkerhuis KM, Rizopoulos D, et al
    Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study.
    Am Heart J. 2018;196:36-48.

    January 2018
  146. MANGLA A, Doukky R, Richardson D, Avery EF, et al
    Design of a bilevel clinical trial targeting adherence in heart failure patients and their providers: The Congestive Heart Failure Adherence Redesign Trial (CHART).
    Am Heart J. 2018;195:139-150.
    PubMed     Abstract available

    December 2017
  147. DA ROSA PR, Rohde LE, Doebber M, Ribeiro ALP, et al
    Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial.
    Am Heart J. 2017;194:125-131.
    PubMed     Abstract available

    November 2017
  148. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    PubMed     Abstract available

    October 2017
  149. CERBIN LP, Ambrosy AP, Mentz RJ
    Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction.
    Am Heart J. 2017;192:e3.

  150. TAYLOR R, Dalal H, Davies R, Doherty P, et al
    Cardiac rehabilitation in heart failure with reduced ejection fraction: A "should take it and not leave it" intervention.
    Am Heart J. 2017;192:e1-e2.

  151. GAGGIN HK, Chen-Tournoux AA, Christenson RH, Doros G, et al
    Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
    Am Heart J. 2017;192:26-37.
    PubMed     Abstract available

  152. ADIR Y, Guazzi M, Offer A, Temporelli PL, et al
    Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities.
    Am Heart J. 2017;192:120-127.
    PubMed     Abstract available

    September 2017
  153. SHERWOOD A, Hill LK, Blumenthal JA, Adams KF Jr, et al
    Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure.
    Am Heart J. 2017;191:82-90.
    PubMed     Abstract available

  154. LUO N, Teng TK, Tay WT, Anand IS, et al
    Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure.
    Am Heart J. 2017;191:75-81.
    PubMed     Abstract available

  155. FRIEDMAN DJ, Al-Khatib SM, Zeitler EP, Han J, et al
    New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Am Heart J. 2017;191:21-29.
    PubMed     Abstract available

    August 2017
  156. AUSTIN CO, Landolfo K, Parikh PP, Patel PC, et al
    Retained cardiac implantable electronic device fragments are not associated with magnetic resonance imaging safety issues, morbidity, or mortality after orthotopic heart transplant.
    Am Heart J. 2017;190:46-53.
    PubMed     Abstract available

  157. GIMPELEWICZ C, Metra M, Cleland JGF, Szecsody P, et al
    Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial.
    Am Heart J. 2017;190:113-122.
    PubMed     Abstract available

    July 2017
  158. RANDOLPH TC, Hellkamp AS, Zeitler EP, Fonarow GC, et al
    Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes.
    Am Heart J. 2017;189:48-58.
    PubMed     Abstract available

  159. HARIKRISHNAN S, Sanjay G, Agarwal A, Kumar NP, et al
    One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India.
    Am Heart J. 2017;189:193-199.
    PubMed     Abstract available

  160. DEVORE AD, Thomas L, Albert NM, Butler J, et al
    Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry.
    Am Heart J. 2017;189:177-183.
    PubMed     Abstract available

  161. CUNNINGHAM JW, Nathan AS, Rhodes J, Shafer K, et al
    Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation.
    Am Heart J. 2017;189:184-192.
    PubMed     Abstract available

    June 2017
  162. TER MAATEN JM, Maggioni AP, Latini R, Masson S, et al
    Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF.
    Am Heart J. 2017;188:189-195.
    PubMed     Abstract available

    Prognostication on the spot! The evolving importance of urinary creatinine in heart failure.
    Am Heart J. 2017;188:186-188.

  164. GOLDBERG SL, Meredith I, Marwick T, Haluska BA, et al
    A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR study.
    Am Heart J. 2017;188:167-174.
    PubMed     Abstract available

  165. RASLAN IR, Brown P, Westerhout CM, Ezekowitz JA, et al
    Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score.
    Am Heart J. 2017;188:127-135.
    PubMed     Abstract available

  166. VUKADINOVIC D, Lavall D, Vukadinovic AN, Pitt B, et al
    True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.
    Am Heart J. 2017;188:99-108.
    PubMed     Abstract available

  167. MOGENSEN UM, Kober L, Kristensen SL, Jhund PS, et al
    The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Am Heart J. 2017;188:35-41.
    PubMed     Abstract available

  168. JOHANSEN ND, Biering-Sorensen T, Jensen JS, Mogelvang R, et al
    Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events.
    Am Heart J. 2017;188:136-146.
    PubMed     Abstract available

    May 2017
  169. PANG PS, Teerlink JR, Boer-Martins L, Gimpelewicz C, et al
    Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
    Am Heart J. 2017;187:62-69.
    PubMed     Abstract available

    April 2017
  170. BAEZA-TRINIDAD R, Mosquera-Lozano JD
    Bendopnea: The next prognostic marker of advanced heart failure?
    Am Heart J. 2017;186:e1.

  171. ECHOUFFO-TCHEUGUI JB, Bishu KG, Fonarow GC, Egede LE, et al
    Trends in health care expenditure among US adults with heart failure: The Medical Expenditure Panel Survey 2002-2011.
    Am Heart J. 2017;186:63-72.
    PubMed     Abstract available

  172. AMBROSY AP, Cerbin LP, DeVore AD, Greene SJ, et al
    Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial.
    Am Heart J. 2017;186:130-138.
    PubMed     Abstract available

  173. FLINT K
    Cardiac rehabilitation in heart failure with reduced ejection fraction: A "take it or leave it" intervention.
    Am Heart J. 2017;186:127-129.

    March 2017
  174. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Abstract available

  175. REEVES GR, Whellan DJ, Duncan P, O'Connor CM, et al
    Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.
    Am Heart J. 2017;185:130-139.
    PubMed     Abstract available

  176. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Abstract available

  177. ROBINSON VM, Bharucha DB, Mahaffey KW, Dorian P, et al
    Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Am Heart J. 2017;185:43-51.
    PubMed     Abstract available

  178. BARRIOS D, Morillo R, Lobo JL, Nieto R, et al
    Assessment of right ventricular function in acute pulmonary embolism.
    Am Heart J. 2017;185:123-129.
    PubMed     Abstract available

  179. HORNE BD, Budge D, Masica AL, Savitz LA, et al
    Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization.
    Am Heart J. 2017;185:101-109.
    PubMed     Abstract available

  180. RICCI F, Mele D, Bianco F, Bucciarelli V, et al
    Right heart-pulmonary circulation unit and cardiac resynchronization therapy.
    Am Heart J. 2017;185:1-16.
    PubMed     Abstract available

    February 2017
  181. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    PubMed     Abstract available

    January 2017
  182. VERMA AK, Schulte PJ, Bittner V, Keteyian SJ, et al
    Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes.
    Am Heart J. 2017;183:54-61.
    PubMed     Abstract available

  183. COX ZL, Lewis CM, Lai P, Lenihan DJ, et al
    Validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center.
    Am Heart J. 2017;183:40-48.
    PubMed     Abstract available

  184. NAGARAJAN V, Hernandez AV, Cauthen CA, Starling RC, et al
    Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure.
    Am Heart J. 2017;183:35-39.
    PubMed     Abstract available

  185. STEINHAUS DA, Mostofsky E, Levitan EB, Dorans KS, et al
    Chocolate intake and incidence of heart failure: Findings from the Cohort of Swedish Men.
    Am Heart J. 2017;183:18-23.
    PubMed     Abstract available

  186. THIBODEAU JT, Jenny BE, Maduka JO, Divanji PH, et al
    Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure.
    Am Heart J. 2017;183:102-107.
    PubMed     Abstract available

    December 2016
  187. ECHOUFFO-TCHEUGUI JB, Xu H, DeVore AD, Schulte PJ, et al
    Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry.
    Am Heart J. 2016;182:9-20.
    PubMed     Abstract available

  188. SPITZER E, Van Mieghem NM, Pibarot P, Hahn RT, et al
    Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial.
    Am Heart J. 2016;182:80-88.
    PubMed     Abstract available

    November 2016
  189. LEE DS, Lee JS, Schull MJ, Grimshaw JM, et al
    Design and rationale for the Acute Congestive Heart Failure Urgent Care Evaluation: The ACUTE Study.
    Am Heart J. 2016;181:60-65.
    PubMed     Abstract available

  190. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Abstract available

    September 2016
  191. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Abstract available

  192. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    PubMed     Abstract available

  193. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Abstract available

  194. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    PubMed     Abstract available

    July 2016
  195. PEGUERO JG, Lo Presti S, Issa O, Podesta C, et al
    Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2.
    Am Heart J. 2016;177:153-9.
    PubMed     Abstract available

  196. KIM EJ, Yin X, Fontes JD, Magnani JW, et al
    Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).
    Am Heart J. 2016;177:138-44.
    PubMed     Abstract available

  197. BAKKESTROM R, Larsen LA, Moller JE, Videbaek L, et al
    Mitral valve regurgitation in twins: Concordance and survival.
    Am Heart J. 2016;177:51-7.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.